Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 8,221–8,280 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

University of California, Santa Cruz1 University of California-Irvine Machine Learning Repository1 University of Cape Town Knowledge Translation Unit1 University of Ceylon Colombo medical school1 University of Chicago Institutional Review Board1 University of Chicago Medicine1 University of Chile1 University of Cincinnati Cancer Center1 University of Colorado Human Immune Monitoring Shared Resource Facility1 University of Colorado School of Medicine1 University of Cordoba1 University of Debrecen1 University of Dhaka Institute of Health Economics1 University of Durham1 University of East Anglia1 University of Exeter Medical School1 University of Exeter Public Health and Sport Sciences1 University of Florence1 University of Florida College of Dentistry1 University of Florida College of Medicine1 University of Florida Institutional Animal Care and Use Committee1 University of Florida, Gainesville1 University of Giessen1 University of Glasgow School of Medical and Life Sciences Ethics Committee1 University of Gondar Comprehensive Specialized Hospital Tertiary Eye Care and Training Center1 University of Gondar, Comprehensive and Specialized Hospital1 University of Gothenburg1 University of Gothenburg, Sweden1 University of Groningen1 University of Health Sciences Research and Training Hospital1 University of Houston Institutional Review Board1 University of Huddersfield1 University of Hull1 University of Illinois1 University of Illinois Hospital in Chicago1 University of Illinois at Urbana-Champaign1 University of Indonesia–Cipto Mangunkusumo Hospital1 University of Iowa Holden Comprehensive Cancer Center1 University of Jyväskylä1 University of Kansas Medical Centre1 University of Karachi1 University of Kent1 University of Kentucky1 University of Kisangani1 University of KwaZulu-Natal Biomedical Research EC1 University of Kwazulu-Natal1 University of Lahore1 University of Lancashire1 University of Latvia Statistics Laboratory1 University of Lausanne1 University of Limerick Education and Health Sciences Research Ethics Committee1 University of Limoges1 University of Liverpool1 University of London1 University of Manchester Research Ethics Committee1 University of Maryland Medical Center1 University of Maryland, Baltimore1 University of Miami Institutional Review Board1 University of Michigan Medical Institutional Review Board1 University of Michigan Medical School1

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 311 of 946

463 Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastases

jitc · abstract · 2025-11-04 · 2 matching annotations

80.3%

J Clin Oncol ipilimumab enzalutamide metastatic castration-resistant prostate cancer mCRPC pancreatic ductal carcinoma prostate cancer Atezolizumab

…static chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–7.Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkop…

470 Multimodal profiling reveals unique and overlapping features of rilvegostomig and PD(x) activity in NSCLC tumor explants

jitc · abstract · 2025-11-04 · 2 matching annotations

80.7%

HBS regulatory board NCT04995523 Rilvegostomig non-small cell lung cancer NSCLC

…eca Human Biological Sample global standard and approved by the HBS regulatory board. All samples used for these work were collected from patients t…

480 Targeting CHCHD3 – cGAS axis: a strategy to remodel the immunosuppressive microenvironment in lung adenocarcinoma with translational implications

jitc · abstract · 2025-11-04 · 2 matching annotations

89.8%

Tianjin Medical University Cancer Institute and Hospital Tianjin Cancer Institute and Hospital TN4510 lung adenocarcinoma CHCHD3 LUAD neoadjuvant chemoimmunotherapy

…ens and information was approved by the Ethics Committee of the Tianjin Medical University Cancer Institute and Hospital (Approve number: bc2022323). All animal experiments were perfor…

481 UCHL1 hijacks tolerogenic dendritic cell maturation and promotes mregDC-Treg crosstalk to nullify checkpoint blockade

jitc · abstract · 2025-11-04 · 2 matching annotations

89.2%

Fudan University Zhongshan Hospital Atezolizumab Bevacizumab Atezo/Bev HCC hepatocellular carcinoma Immune-checkpoint blockade therapies

…udy was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (IRB number: B2021-464).Consent Written informed consent was ob…

491 A single-arm clinical trial of iNeo-Vac-R01 for advanced digestive system tumors refractory to standard therapy

jitc · abstract · 2025-11-04 · 2 matching annotations

97.0%

Zhejiang University School of Medicine Sir Run Run Shaw Hospital iNeo-Vac-R01 pancreatic cancer gastric cancer cholangiocarcinoma esophageal cancer advanced digestive system malignancies

…ethics committees of Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine. The ID of the approval is 2023-0465. Written informed consent …

493 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.1%

West China Hospital of Sichuan University Institutional Review Board CRC Akk immunotherapy ClinicalTrials.gov MSS CRC PD-1 inhibitors

…number: NCT06865521).All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…

494 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.3%

West China Hospital of Sichuan University Akk Institutional Review Board CRC immunotherapy ClinicalTrials.gov MSS CRC

…umber: NCT06865521). All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…

498 Integrated scRNAseq, TCR repertoire and spatial transcriptomic analysis reveals immune remodeling induced by combined BRAF/MEK/PD-1 inhibition in metastatic BRAFV600E colorectal cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

80.7%

…23;29(2):458–466.Ethics Approval This study was approved by the DF/HCC IRB as protocol 18-144 (see also ClinicalTrials.gov NCT03668431).…

500 Biomarker identification of early response and resistance to combinatorial anti-angiogenic and immune-checkpoint blockade therapy in the recurrent ovarian cancer setting

jitc · abstract · 2025-11-04 · 2 matching annotations

90.7%

EORTC-1508GCG atezolizumab bevacizumab atezolizumab-containing High-grade serous ovarian cancer aspirin PROC low-dose aspirin PD-L1 blockade platinum-resistant ovarian cancer+1 more

…elial barrier, potentially synergizing with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab…

502 Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC

jitc · abstract · 2025-11-04 · 2 matching annotations

89.1%

Mayo Clinic South Central - Oxford TG4050 HNSCC NCT04183166

…00 (EudraCT 2018-003267-58) Initial approval on 26 Mar 2020 US: Mayo Clinic Institutional Review Boards ID: 20-007421 Initial approval on 1…

504 Biological mechanisms of resistance to macrophage checkpoint inhibitors in relapsed B-cell non-Hodgkin lymphoma

jitc · abstract · 2025-11-04 · 2 matching annotations

87.8%

NCT05025800 Clin Cancer Res evorpacept lenalidomide rituximab B-cell non-hodgkin lymphoma B-NHL ALX148

…checkpoint inhibitor.Methods In this single-arm phase 1 trial ( NCT05025800), adult patients with relapsed indolent B-NHL received evorpace…

516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors

jitc · abstract · 2025-11-04 · 2 matching annotations

92.7%

Memorial Sloan Kettering Cancer Center Institutional Review Board Columbia University Institutional Review Board rituximab tocilizumab bullous pemphigoid prednisone arthritis osteoporosis

…view Board (IRB # AAAS9173). The study was also approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB protocol number: 21-519).Abstract 516 Figure 1Tocilizumab …